NitrosamineN-Nitroso Compounds
Nitrosamines are a class of probable human carcinogens that can form as impurities in drug substances and products. Regulators expect manufacturers to assess risk, test where risk exists, and keep levels at or below acceptable intake limits, including for nitrosamine drug substance-related impurities (NDSRIs).

On this page · 19 sections
- 1What nitrosamines are
- 2Where they come from
- 3The regulatory three-step approach
- 4Acceptable intake limits
- 5Analytical testing
- 6Mitigation options
- 7Common pitfalls
- 8How a nitrosamine risk assessment is usually run
- 9Keeping supplier evidence current
- 10Inside V5: supplier, lab and change records
- 11Explain it for your operation
- 12Excipients and nitrite
- 13Supplier collaboration
- 14Lifecycle management
- 15A practical nitrosamine example
- 16A proportionate implementation plan
- 17Internal review questions
- 18Records and evidence to retain
- 19Questions to ask when evaluating software
How does Nitrosamine apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What nitrosamines are
Nitrosamines form when nitrosating agents such as nitrites react with secondary or tertiary amines under certain conditions. Small molecules like NDMA and NDEA drew attention after detections in several drug classes from 2018.
NDSRIs form from the drug molecule itself and are specific to each active ingredient.
02Where they come from
Sources include reagents, solvents and catalysts in API synthesis, recovered solvents, contaminated raw materials, excipients containing nitrite, packaging materials and degradation during storage.
Risk assessment must consider the whole lifecycle, not only synthesis.
03The regulatory three-step approach
Regulators describe a sequence: assess risk, perform confirmatory testing where risk is identified, and implement changes to reduce levels where needed, reporting through the appropriate regulatory route.
Timelines and procedures are set by each agency; check current guidance.
04Acceptable intake limits
Acceptable intake (AI) limits, often in nanograms per day, are set based on carcinogenic potency. FDA and EMA publish recommended limits, including a categorisation approach for NDSRIs.
Convert AI to concentration limits using the product's maximum daily dose.
05Analytical testing
Very low limits require sensitive, validated methods, commonly LC-MS/MS or GC-MS. Methods must avoid creating nitrosamines during sample preparation.
Report detection and quantitation limits with results.
06Mitigation options
Options include changing synthetic routes or reagents, controlling nitrite in excipients, adding antioxidants or pH modifiers in formulation, and changing packaging.
Changes need change control, stability data and regulatory filings as applicable.
07Common pitfalls
Pitfalls include risk assessments that ignore excipients or packaging, methods with insufficient sensitivity, and treating one negative result as permanent assurance.
Revisit assessments when suppliers or processes change.
08How a nitrosamine risk assessment is usually run
- List every source of secondary or tertiary amines and nitrosating agents across the synthesis route, excipients, water, packaging and process aids.
- Ask suppliers for their own nitrosamine risk statements and record the date and scope of each statement.
- Rank products and materials by likelihood of formation or carry-over, and document the reasoning, not only the score.
- Where risk cannot be ruled out on paper, plan confirmatory testing with a suitably sensitive and validated method.
- Feed any confirmed presence into deviation, change control and, where needed, regulatory notification under your own procedures.
Regulators expect the assessment to be revisited when a supplier, route, excipient or packaging component changes, so the assessment is a living record rather than a one-time report.
09Keeping supplier evidence current
Most nitrosamine risk enters through purchased materials. A practical control is to link each approved material to its latest supplier statement and to set a review date, so an expired or missing statement is visible before the material is used in a new batch.
Purchasing, quality and regulatory teams should agree who chases suppliers and who decides whether a statement is adequate. That decision stays with qualified people; software can only show what is missing or overdue.
10Inside V5: supplier, lab and change records
V5 can hold supplier and material records, laboratory results against lots, deviations and change control records, helping teams keep nitrosamine risk evidence connected to specific materials and batches.
V5 does not perform risk assessments, set AI limits or test samples; qualified scientists and quality personnel do.
11Explain it for your operation
For one product, list every material and packaging component with potential nitrite or amine contribution and the evidence held for each.
Prioritise gaps where evidence is missing or old.
12Excipients and nitrite
Many common excipients contain trace nitrite, which can nitrosate susceptible amines during manufacturing or storage. Supplier data on nitrite levels supports risk assessment and grade selection.
Variability between excipient lots and suppliers can be significant.
13Supplier collaboration
API and excipient suppliers hold critical information about routes, reagents and solvents. Questionnaires and quality agreements should request and update it.
Supplier changes must trigger reassessment.
14Lifecycle management
Nitrosamine risk is not a one-time project. New products, route changes, new suppliers, packaging changes and new regulatory limits all require review.
Keep the assessment as a controlled document with version history.
15A practical nitrosamine example
A risk assessment for a tablet identifies a secondary amine in the API and nitrite in one excipient grade. Confirmatory LC-MS/MS testing finds an NDSRI below its acceptable intake-derived limit but rising on stability.
The company switches to a low-nitrite excipient grade under change control, monitors stability and files the change through the appropriate regulatory route.
16A proportionate implementation plan
- Confirm the applicable requirement, product scope and decision owner.
- Map the current method and the records already available.
- Define terms, responsibilities, evidence and exception handling in the approved procedure.
- Pilot the method on one representative process and challenge a difficult exception.
- Train affected roles, approve the change and monitor whether the method works as intended.
- Review after significant change and retain a transparent history of decisions.
Scale the formality to risk and complexity. A small operation still needs clear responsibilities and reconstructable evidence, while a multi-site operation also needs harmonised definitions, governance and comparison rules.
17Internal review questions
- Can a reviewer identify the source, owner, method and current approved version?
- Do summaries reconcile to original records and include unfavourable or missing evidence?
- Are exceptions visible, assessed and linked to the affected material, product or process?
- Are actions assigned, overdue items escalated and effectiveness reviewed?
- Have changes in product, supplier, equipment, method or regulation triggered reassessment?
- Does the record distinguish system support from the decision an authorised person made?
18Records and evidence to retain
- Approved scope, definitions and responsibilities for Nitrosamine Impurities.
- Source records and identifiers that let a reviewer reconstruct the work.
- Methods, assumptions, calculations, exclusions and any data-quality limitations.
- Exceptions, investigations, decisions, approvals and resulting actions.
- Version history showing when the approach changed and why.
Records should be proportionate to the decision and usable by someone who was not present. Preserve original evidence and corrections rather than replacing it with an unexplained summary.
19Questions to ask when evaluating software
- Can users trace every summary value back to its source record and version?
- How are roles, permissions, signatures and corrections recorded?
- Can the workflow reflect our approved procedure without inventing a universal rule?
- What happens during an outage, and how are later entries distinguished?
- Can we test the highest-risk exception with realistic data before committing?
- Which decisions remain explicitly assigned to an authorised person?
Frequently asked questions
Q.What is Nitrosamine Impurities?+
Nitrosamines are a class of probable human carcinogens that can form as impurities in drug substances and products. Regulators expect manufacturers to assess risk, test where risk exists, and keep levels at or below acceptable intake limits, including for nitrosamine drug substance-related impurities (NDSRIs).
Q.Is Nitrosamine Impurities required in every operation?+
The applicable product rules, market, risk and approved quality system determine what is required. The method should be justified for the operation rather than copied without context.
Q.Can software make the final decision?+
No. Software can organise records, calculations and workflow, but authorised people remain responsible for planning commitments, scientific, quality and disposition decisions.
Q.How should a site start?+
Choose one bounded process, define the decision and evidence, test the method with real records, correct gaps, then expand under change control.
Q.What evidence should be retained?+
Keep the approved method, source records, assumptions, exceptions, review, decision, approval and any resulting action with enough context to reconstruct the work.
Q.Does a nitrosamine risk assessment need repeating?+
Yes, when relevant inputs change, such as a new supplier, synthesis route, excipient or packaging component, and at the periodic review interval set in your procedures.
Primary sources
Want to see how Nitrosamine could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
